Routine restaging PET/CT and detection of initial recurrence in sentinel lymph node positive stage III melanoma

Abstract Background Follow-up of patients with sentinel lymph node–positive stage III melanoma uses history, physical exam, and cross-sectional imaging. The aim of this study was to evaluate positron emission tomographic (PET)/computed tomographic (CT) scans in the detection of recurrence. Methods F...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The American journal of surgery 2014-04, Vol.207 (4), p.549-554
Hauptverfasser: Baker, Justin J., M.D, Meyers, Michael O., M.D, Frank, Jill, M.S, Amos, Keith D., M.D, Stitzenberg, Karyn B., M.D, Ollila, David W., M.D
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Background Follow-up of patients with sentinel lymph node–positive stage III melanoma uses history, physical exam, and cross-sectional imaging. The aim of this study was to evaluate positron emission tomographic (PET)/computed tomographic (CT) scans in the detection of recurrence. Methods From 2003 to 2009, a single-institution prospective database of all cutaneous melanoma patients was used to identify sentinel lymph node–positive stage III patients with disease-free survival >1 year and 1 restaging PET/CT scan. Results Thirty-eight patients were identified, with a median follow-up period of 27.5 months. Seven (18%) developed recurrence (median time to recurrence, 25 months). Recurrences were detected as follows: 3 by patients, 1 by physician, 1 by PET/CT scan and lactate dehydrogenase, 1 by PET/CT scan, and 1 by brain magnetic resonance imaging. One hundred eight follow-up PET/CT scans were performed. Two of 38 patients had asymptomatic metastases detected by routine restaging PET/CT scan, and there were 9 scans with false-positive results. Conclusions With short follow-up, the utility of routine PET/CT scans in identifying unsuspected recurrence in patients with sentinel lymph node–positive stage III melanoma appears minimal.
ISSN:0002-9610
1879-1883
DOI:10.1016/j.amjsurg.2013.04.012